ResMed Inc
(BSP:R1MD34)
R$
371.16
0 (0%)
Market Cap: 217.94 Bil
Enterprise Value: 220.49 Bil
PE Ratio: 33.02
PB Ratio: 7.04
GF Score: 85/100 Resmed Inc at RBC Capital Markets Global Healthcare Conference Transcript
May 14, 2024 / 08:05PM GMT
Release Date Price:
R$279.44
Craig Wong;Pan
RBC Capital Markets, Research Division - Director of Equity Research & Equity Research Analyst
And I'm one of the health care analysts at RBC. Welcome to RBC's Global Healthcare Conference 2024. I'd like to welcome with me to the stage are Carlos Nunez, the Chief Medical Officer at ResMed; and Amy Wakeham the Chief Investor Relations Officer at ResMed. Welcome.
Amy Wakeham
ResMed Inc. - Chief IR Officer
Thank you.
Carlos M. Nunez
ResMed Inc. - Chief Medical Officer
Thank you.
Questions & Answers
Craig Wong;Pan;Carlos M. Nunez
RBC Capital Markets, Research Division - Director of Equity Research & Equity Research Analyst;ResMed Inc. - Chief
So I just want to get started. Carlos, could I get your thoughts on the top line results of the SURMOUNT-OSA study? And more importantly, your expectations for how that might evolve or affect the way that sleep apnea is treated?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot